Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

BioFire Defense LLC, part of Compagnie Merieux Alliance SAS, is an American company located in Salt Lake City, UT, that develops, manufactures and sells biological diagnostic substances. Robert J. Lollini is currently the CEO of the firm.

AxioMx, founded in 2012 and based in Branford, Connecticut is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.

Affymetrix, Inc. was an American company that manufactured DNA microarrays; it was based in Santa Clara, California, United States. The company was acquired by Thermo Fisher Scientific in March 2016. The company was founded by Stephen Fodor in 1992. It began as a unit in Affymax N.V. in 1991 by Fodor's group, which had in the late 1980s developed methods for fabricating DNA microarrays, called "GeneChip" according to the Affymetrix trademark, using semiconductor manufacturing techniques. The company's first product, an HIV genotyping GeneChip, was introduced in 1994 and the company went public in 1996. As a result of its pioneering work and the ensuing popularity of microarray products, Affymetrix derived significant benefit from its patent portfolio in this area.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

KeyGene NV provides its partners and customers in the plant breeding industry contract research, partnerships and molecular genetic services. It delivers novel enabling technologies and applications to support companies and institutes that carry out fundamental or applied genetic genomic research and that seek to enhance the quality of their products through the improvement of their genetic material. The company was established in 1989 and is headquartered in Wageningen, the Netherlands.

Part of PerkinElmer, Inc. (United States), Perkin Elmer Ltd. is a South Korean company. The firm manufactures pharmaceutical products.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan.

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

Develops and distributes pharmaceutical products

GenVault is dedicated to stabilizing biosamples and to the integration of biosample transport, storage and retrieval, in a way that meshes seamlessly with day-to-day lab operations: thus simplifying sample sharing for customers in genomic medicine, discovery and identification. Today, we are empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies, to more fully leverage the rapidly growing genomics industry. GenVault’s proprietary dry-state storage platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Currently work is proceeding on equivalent storage technologies for protein and RNA. The need for such sample management solutions is growing at an exponential rate, as more and more samples are collected worldwide for disease diagnosis, research, identification and criminal investigations

Founded by scientists specialised in Nanotechnology, Medicinal Chemistry and Artificial Intelligence, we are on a mission to enable early detection of cancer through a rapid and affordable blood test Backed by academics at top universities, clinicians, industrial leaders, and Entrepreneur First.

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California in 1971, but conducted most of its operations in nearby Emeryville. Before merging with another company in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

PerSeptive Biosystems develops instrumentation systems and consumable products for the purification, analysis, and synthesis of biomolecules. It develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers of PerSeptive Biosystems use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Founded in 1989, PerSeptive Biosystems is based in Framingham, Massachusetts. Currently, it operates as a subsidiary of Life Technologies Corporation.

Axaron Bioscience AG is a German private company located in Heidelberg with domestic subsidiaries. The firm develops biotechnologies.

Enzynomics Co. Ltd. is a South Korean private company located in Yuseong-gu that develops and distributes laboratory-use enzymes. The firm was founded in 2007. Yeon-Soo Seo is currently the CEO of the company.